drugset / Trial / NCT04582136
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
Phase 3
Active not recruiting
146 enrolled
Chinese SLE Treatment And Research Group
Beijing Municipal Science & Technology Commission · collabNorth China Pharmaceutical Group Corporation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center, double-blinded, randomized, placebo-controlled, phase 3 study to evaluate the efficacy and safety of sirolimus administered in addition to standard therapy, in patients with active SLE disease.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2025-04-21
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 1.5 mg | Oral |